Related references
Note: Only part of the references are listed.Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX
Otto Metzger-Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
James L. Khatcheressian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
B. Gibert et al.
BRITISH JOURNAL OF CANCER (2012)
HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway
Y. Yao et al.
CANCER GENE THERAPY (2012)
Transcriptional Network Analysis Identifies BACH1 as a Master Regulator of Breast Cancer Bone Metastasis
Yajun Liang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bradley N. Bidwell et al.
NATURE MEDICINE (2012)
American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
Catherine H. Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
Pierre P Major et al.
BMC CANCER (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery
Takayoshi Kiba et al.
BMC CANCER (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Estrogen receptors and distinct patterns of breast cancer relapse
KR Hess et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Share Paper
